Journal article
An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
Kidney international, Vol.106(3), pp.326-336
09/2024
DOI: 10.1016/j.kint.2024.05.021
PMID: 39174192
Abstract
The term atypical hemolytic uremic syndrome has been in use since the mid-1970s. It was initially used to describe the familial or sporadic form of hemolytic uremic syndrome as opposed to the epidemic, typical form of the disease. Over time, the atypical hemolytic uremic syndrome term has evolved into being used to refer to anything that is not Shiga toxin–associated hemolytic uremic syndrome. The term describes a heterogeneous group of diseases of disparate causes, a circumstance that makes defining disease-specific natural history and/or targeted treatment approaches challenging. A working group of specialty-specific experts in the thrombotic microangiopathies was convened to review the validity of this broad term in an era of swiftly advancing science and targeted therapeutics. A Delphi approach was used to define and interrogate some of the key issues related to the atypical hemolytic uremic syndrome nomenclature.
Details
- Title: Subtitle
- An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
- Creators
- Carla M. Nester - University of IowaDavid L. Feldman - National Kidney FoundationRichard Burwick - Pomona Valley Hospital Medical CenterSpero Cataland - The Ohio State UniversityShruti Chaturvedi - Johns Hopkins University School of MedicineH. Terence Cook - Imperial College Healthcare NHS TrustAdam Cuker - University of PennsylvaniaBradley P. Dixon - University of Colorado Anschutz Medical CampusFadi Fakhouri - University of LausanneSangeeta R. Hingorani - University of Washington School of MedicineAnuja Java - Washington University in St. Louis School of MedicineNicole C.A.J. van de Kar - Radboud University Medical CenterDavid Kavanagh - Newcastle upon Tyne Hospitals NHS Foundation TrustNelson Leung - Mayo ClinicChristoph Licht - Hospital for Sick ChildrenMarina Noris - Istituto di Ricerche Farmacologiche Mario Negri IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Bergamo, ItalyMichelle M. O’Shaughnessy - Ollscoil na Gaillimhe – University of GalwaySamir V. Parikh - The University of Texas Southwestern Medical CenterRichard J.H. Smith - University of IowaFlora Peyandi - Fondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicoC. John Sperati - Johns Hopkins University School of MedicineGiuseppe Remuzzi - Istituto di Ricerche Farmacologiche Mario Negri IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Bergamo, ItalyMeryl Waldman - National Institute of Diabetes and Digestive and Kidney DiseasesPatrick Walker - Arkana LaboratoriesMarina Vivarelli - Bambino Gesù Children's Hospital
- Resource Type
- Journal article
- Publication Details
- Kidney international, Vol.106(3), pp.326-336
- DOI
- 10.1016/j.kint.2024.05.021
- PMID
- 39174192
- NLM abbreviation
- Kidney Int
- ISSN
- 0085-2538
- eISSN
- 1523-1755
- Publisher
- Elsevier Inc
- Grant note
This initiative was initiated and coordinated by the National Kidney Foundation, and we gratefully acknowledge Alexion Pharmaceuticals for supporting this work. Neither organization had influence on the article content. We also gratefully acknowledge the patient representatives Linda Burke and Len Woodward on behalf of aHUS Alliance Global Action for thoughtful feedback on the article.
- Language
- English
- Date published
- 09/2024
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Molecular Physiology and Biophysics; Anatomy and Cell Biology; Nephrology, Dialysis and Transplantation; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Otolaryngology; Internal Medicine
- Record Identifier
- 9984696788902771
Metrics
26 Record Views